Elicio Therapeutics, Inc. 8-K

What Happened

• On March 16, 2026, Elicio Therapeutics, Inc. (ELTX) filed an 8-K announcing an at-the-market (ATM) equity sales agreement that allows the company to issue and sell up to $100.0 million of its common stock through B. Riley Securities, JonesTrading Institutional Services and Ladenburg Thalmann. Sales will be made under the company’s existing Form S-3 registration statement (File No. 333-293861).
• The company also notified JonesTrading that it was terminating a prior Capital on Demand™ (ATM) sales agreement that had authorized up to $40.0 million of sales; JonesTrading waived the usual notice periods and the termination is effective upon delivery, with no termination penalties.

Key Details

• Aggregate offering size: up to $100.0 million of common stock under the new Sales Agreement (dated March 16, 2026).
• Agents: B. Riley Securities, Inc.; JonesTrading Institutional Services LLC; Ladenburg Thalmann & Co. Inc.
• Agent fee: 3.0% of gross proceeds on any Placement Shares sold through the Agents.
• Sales mechanics: shares may be sold "at the market" (including on The Nasdaq Capital Market) from time to time at the company’s discretion; the company is not required to sell any shares.
• Prior agreement: the earlier JonesTrading ATM authorized up to $40.0 million (originally disclosed June 3, 2024 / effective June 11, 2024) and has been terminated effective March 16, 2026.

Why It Matters

• This ATM program gives Elicio flexible, on-demand access to capital — the company can raise funds quickly by selling shares into the market when it chooses, subject to market conditions.
• For investors, any future sales under the ATM could dilute existing shareholders and increase share count; the actual impact depends on how many shares are sold and at what prices.
• Costs and terms: the company will pay a 3% sales commission and has provided customary indemnities to the agents; there is no obligation to use the ATM and the agreement can be terminated with short notice.